GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (FRA:MYD) » Definitions » Cyclically Adjusted Book per Share

Myriad Genetics (FRA:MYD) Cyclically Adjusted Book per Share : €12.87 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Myriad Genetics's adjusted book value per share for the three months ended in Mar. 2024 was €7.726. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €12.87 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Myriad Genetics's average Cyclically Adjusted Book Growth Rate was 0.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 7.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 8.70% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Myriad Genetics was 12.20% per year. The lowest was 7.50% per year. And the median was 10.95% per year.

As of today (2024-05-19), Myriad Genetics's current stock price is €22.60. Myriad Genetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €12.87. Myriad Genetics's Cyclically Adjusted PB Ratio of today is 1.76.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Myriad Genetics was 7.10. The lowest was 0.97. And the median was 2.80.


Myriad Genetics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Myriad Genetics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cyclically Adjusted Book per Share Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.71 9.50 11.09 12.74 12.75

Myriad Genetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.25 12.58 13.71 12.75 12.87

Competitive Comparison of Myriad Genetics's Cyclically Adjusted Book per Share

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted PB Ratio falls into.



Myriad Genetics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.726/131.7762*131.7762
=7.726

Current CPI (Mar. 2024) = 131.7762.

Myriad Genetics Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.200 100.560 9.435
201409 7.572 100.428 9.936
201412 7.873 99.070 10.472
201503 8.827 99.621 11.676
201506 8.562 100.684 11.206
201509 8.821 100.392 11.579
201512 9.883 99.792 13.051
201603 9.824 100.470 12.885
201606 9.635 101.688 12.486
201609 9.581 101.861 12.395
201612 10.202 101.863 13.198
201703 10.273 102.862 13.161
201706 9.998 103.349 12.748
201709 10.559 104.136 13.362
201712 11.131 104.011 14.102
201803 11.010 105.290 13.780
201806 11.714 106.317 14.519
201809 12.645 106.507 15.645
201812 12.779 105.998 15.887
201903 13.044 107.251 16.027
201906 13.111 108.070 15.987
201909 13.114 108.329 15.952
201912 13.013 108.420 15.816
202003 11.749 108.902 14.217
202006 10.915 108.767 13.224
202009 10.266 109.815 12.319
202012 0.000 109.897 0.000
202103 9.585 111.754 11.302
202106 9.641 114.631 11.083
202109 10.330 115.734 11.762
202112 10.706 117.630 11.994
202203 10.784 121.301 11.715
202206 11.120 125.017 11.721
202209 11.443 125.227 12.042
202212 10.298 125.222 10.837
202303 9.571 127.348 9.904
202306 8.286 128.729 8.482
202309 7.803 129.860 7.918
202312 7.989 129.419 8.134
202403 7.726 131.776 7.726

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Myriad Genetics  (FRA:MYD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Myriad Genetics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=22.60/12.87
=1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Myriad Genetics was 7.10. The lowest was 0.97. And the median was 2.80.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Myriad Genetics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (FRA:MYD) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.